Celgene/Novartis d-methylphenidate
Executive Summary
Novartis will fund all further product development and marketing expenses in the approval process under a worldwide license (excluding Canada) to market the chirally pure version of Ritalin (methylphenidate). Celgene expects to file the d-methylphenidate NDA for treatment of attention deficit disorder during the third quarter. The chiral product will carry a Ritalin family name. Celgene's previous name for the d-methylphenidate product, Attenade, will no longer be used